Flag of the European Union EU Clinical Trials Register Help

Clinical trials for wound care

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43801   clinical trials with a EudraCT protocol, of which   7272   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    224 result(s) found for: wound care. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-002669-23 Sponsor Protocol Number: PROFITOP Start Date*: 2017-12-21
    Sponsor Name:Hospital General Universitari de Granollers
    Full Title: Prophylaxis of surgical wound infection with topical antibiotics
    Medical condition: Surgical wound infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10048038 Wound infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003390-26 Sponsor Protocol Number: BSG-12 Start Date*: 2012-12-18
    Sponsor Name:Birken AG
    Full Title: Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in...
    Medical condition: Split-Thickness Skin Graft Donor Sites
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10041667 Split thickness skin graft LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-000777-23 Sponsor Protocol Number: BSH-12 Start Date*: 2012-07-05
    Sponsor Name:Birken AG
    Full Title: Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in...
    Medical condition: Split-Thickness Skin Graft Donor Sites
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10041667 Split thickness skin graft LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FI (Completed) AT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004527-67 Sponsor Protocol Number: DT-DP-DFU-CR-04 Start Date*: 2018-08-06
    Sponsor Name:DermaTools Biotech GmbH
    Full Title: A Randomised Dose Finding Study Comparing The Safety And Efficacy Of three blinded doses of Diperoxochloric Acid (DPOCl, DermaPro®) and A Standard Moist Wound Dressing In Patients With Non-Healing...
    Medical condition: Diabetic foot ulcer with mean diameter between 1.5 and 4 cm after débridement if indicated), Wound stage Wagner grade I or II, Armstrong stadium A or C (for Wagner-Armstrong-Classification), tr...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003066-24 Sponsor Protocol Number: MW2012-01-01 Start Date*: 2014-12-17
    Sponsor Name:MediWound Ltd.
    Full Title: A multicenter, multinational, randomized, controlled, open label study, performed in children with thermal burns, to evaluate the efficacy and safety of NexoBrid as compared to standard of care (SO...
    Medical condition: The study objective is to evaluate the safety and clinical benefit of NexoBrid in hospitalized children (0-18 years) with deep partial and/or full thickness thermal burns of 1-30% TBSA and to compa...
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004863 10043418 Thermal burns HLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Ongoing) SK (Completed) DE (Ongoing) BE (Completed) AT (Prematurely Ended) BG (Prematurely Ended) NL (Prematurely Ended) FR (Ongoing) SE (Ongoing) GB (GB - no longer in EU/EEA) HU (Completed) PL (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000476-14 Sponsor Protocol Number: TCI_BRIVA Start Date*: 2013-05-07
    Sponsor Name:LANDSTINGET I ÖSTERGÖTLAND
    Full Title: TARGET-CONTROLLED INFUSION (TCI) WITH PROPOFOL AND REMIFENTANIL AS ANALGO-SEDATION IN WOUND CARE IN PATIENTS WITH BURNS
    Medical condition: Burn patients who need analgo-sedation during wound care.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004863 10028175 Multiple burns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000362-38 Sponsor Protocol Number: BBW-11 Start Date*: 2012-06-18
    Sponsor Name:Birken AG
    Full Title: Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in...
    Medical condition: Superficial partial-thickness (grade 2a) burn wounds
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10006802 Burns second degree PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004109-15 Sponsor Protocol Number: 1ABC Start Date*: 2017-12-13
    Sponsor Name:Medical University of Warsaw
    Full Title: Evaluation of the safety and efficacy of the treatment of chronic wounds in diabetic foot syndrome with the use of autologous stem cells isolated from adipose tissue - within the project: "Therapeu...
    Medical condition: Diabetic foot ulcer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000563-69 Sponsor Protocol Number: IPCT003 Start Date*: 2021-06-04
    Sponsor Name:Ilya Pharma AB
    Full Title: A Randomized, Double-Blind, Placebo-controlled, Parallel, Exploratory Phase 2a Study to Evaluate Safety and Biological Effect on Wound Healing of ILP100 in Subjects with Diabetic Foot Ulcers
    Medical condition: Diabetic foot ulcers a systemic complication in diabetes mellitus type 1 or 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005092-18 Sponsor Protocol Number: CS I-020502/01 Start Date*: 2007-01-08
    Sponsor Name:KUROS BIOSURGERY AG
    Full Title: A phase 2a, multi-centre, controlled study of the safety and efficacy of wound healing gel I-020502 in patients undergoing autologous meshed skin grafting.
    Medical condition: Deep partial-thickness and full-thickness burns require grafting procedures to achieve wound healing and closure. Autologous grafting eliminates the risk of transmissible diseases but may be compli...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10053615 Thermal burn LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021015-16 Sponsor Protocol Number: TFM-CL3-002 Start Date*: 2010-09-30
    Sponsor Name:Olympus France SAS
    Full Title: A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment with Trafermin 0.01% Spray in Patients with Diabetic Foot Ulcer of Neuropathic ...
    Medical condition: Wound closure rate of diabetic foot ulcers (DFUs) of neuropathic origin.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Completed) DK (Completed) SE (Completed) DE (Completed) NL (Completed) HU (Completed) SK (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001301-90 Sponsor Protocol Number: SNFCT2017-06 Start Date*: 2020-05-20
    Sponsor Name:Sanifit Therapeutics S.A
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When added to Background Care for the Treatment of Calciphylaxis.
    Medical condition: Calciphylaxis (Calcific uremic arteriolopathy [CUA])
    Disease: Version SOC Term Classification Code Term Level
    21.0 10027433 - Metabolism and nutrition disorders 10051714 Calciphylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) PL (Completed) BE (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-004728-14 Sponsor Protocol Number: TCP25-001 Start Date*: 2022-03-10
    Sponsor Name:Xinnate AB
    Full Title: A Three-part, Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Topical Doses of TCP-25 in Healthy Male and Female Volunteers with Epidermal Suction Blister Wounds and in...
    Medical condition: TCP-25 gel targets both bacteria and inflammation, aspects common to many wounds and is being developed for a range of wound healing indications including prevention and treatment of infection and ...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003326-23 Sponsor Protocol Number: DT-DP-DFU-CR-05 Start Date*: 2021-07-05
    Sponsor Name:DermaTools Biotech GmbH
    Full Title: A Prospective, Randomized, Double-Blind, Vehicle-Controlled Study To Evaluate The Safety and Efficacy of Diperoxochloric Acid (DPOCl, DermaPro®) In Patients With Non-Healing Diabetic Foot Ulcers
    Medical condition: 3. Diabetic foot ulcer treated unsuccessfully for at least 4 weeks with mean diameter between 1.5 and 4 cm after débridement
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015749-22 Sponsor Protocol Number: ADATOP Start Date*: 2010-12-22
    Sponsor Name:University of Leipzig
    Full Title: A prospective, monocentric clinical trial with adalimumab for topical treatment in chronic wounds
    Medical condition: Chronic stasis ulcer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10047246 Venous stasis ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006013-11 Sponsor Protocol Number: HOTPANTS Start Date*: 2022-08-29
    Sponsor Name:Erasmus MC, department of dermatology
    Full Title: Hyperbaric Oxygen Therapy for Pyoderma gangrenosum As a New Treatment Strategy
    Medical condition: Pyoderma gangrenosum
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000234-57 Sponsor Protocol Number: allo-APZ2-DFU-II-01 Start Date*: 2017-08-07
    Sponsor Name:RHEACELL GmbH & Co. KG
    Full Title: An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-DFU on wound healing of diabetic neuropathic ulcer (DFU).
    Medical condition: Diabetic neuropathic ulcer (DFU)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000214-42 Sponsor Protocol Number: 755-201-EB Start Date*: Information not available in EudraCT
    Sponsor Name:InMed Pharmaceuticals Inc.
    Full Title: A Randomised, Double-Blind, Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (cannabinol) Cream in Patients with Epidermolysis Bullosa.
    Medical condition: Epidermolysis bullosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) AT (Completed) GR (Ongoing) IT (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003104-39 Sponsor Protocol Number: SIS-05-2013 Start Date*: 2013-12-18
    Sponsor Name:Fakultní nemocnice Ostrava,Czech republic
    Full Title: Randomised Clinical Study of Safety of Efficacy of Extracelular Matrix and Autologous Platelet Rich Plasma Concentrate for Wound Healing (Leg Ulcers Biodesign Wound Healing – LEGEND(A) Study) In...
    Medical condition: Chronical ischemic and venous ulcers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001672-55 Sponsor Protocol Number: MW2010-03-02 Start Date*: 2014-09-22
    Sponsor Name:MediWound Ltd.
    Full Title: A multicenter, multinational, randomized, controlled, assessor blinded study, performed in subjects with thermal burns, to evaluate the efficacy and safety of NexoBrid compared to Gel Vehicle and c...
    Medical condition: The study objective is to evaluate the efficacy and safety of NexoBrid in removing burn eschar in hospitalized subjects with thermal burns.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004863 10043418 Thermal burns HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) RO (Completed) LV (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA